Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?

Date: Wednesday, May 28th, 2025   
Time: 11:00AM-12:00PM (ET)   

11:00 – 11:05 am       
Introduction

* Sara Demy, Founder & CEO, Demy-Colton
* Steve Brozak, President and Co-founder, WBB Securities

11:05 – 11:10 am       
Understanding the Shortcomings of CAR-T Therapy
* Helen Heslop, MD, Professor, Department of Medicine & Pediatrics and Director, Center for Cell and Gene Therapy, Baylor College of Medicine

11:10 – 11:15 am       
Overcoming the Current Limitations of CAR-T Therapy
* Malcolm Brenner, MD, PhD, Professor, Center for Cell & Gene Therapy and Founding Director, Center for Cell and Gene Therapy, Baylor College of Medicine

11:15 – 11:20 am       
MAR-T Cells as a Novel Approach to Address Unmet Needs
* Juan Vera, MD, President & CEO, Marker Therapeutics

11:20 – 11:50 am   
Roundtable Discussion

Moderator:
* Richard Marfuggi, MD, DMH, Board Certified Plastic Surgeon

Panelists:
* Malcolm Brenner, MD, PhD, Professor, Center for Cell & Gene Therapy and Founding Director, Center for Cell and Gene Therapy, Baylor College of Medicine
* Helen Heslop, MD, Professor, Department of Medicine & Pediatrics and Director, Center for Cell and Gene Therapy, Baylor College of Medicine
* Manali Kamdar, MD, Associate Professor of Medicine and Clinical Director of Lymphoma Services, University of Colorado
* Geoffrey Shouse, DO, PhD, Hematologist-Oncologist & Researcher, City of Hope
* Juan Vera, MD, President & CEO, Marker Therapeutics

11:50 – 12:00 pm  
Q&A